Views & Analysis Growing up different and not knowing why: My experience of r... Protracted diagnostic odysseys don’t only block access to rare disease treatments, they also leave people facing emotional turmoil all alone.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.